AVAILABLE MEDICINE FOR Eltrombopag
There are no products to list.
Introduction to Eltrombopag
Eltrombopag is a thrombopoietin receptor agonist that helps increase platelet counts in people with certain conditions like chronic immune thrombocytopenia (ITP) or thrombocytopenia associated with hepatitis C or aplastic anemia.
How it Works:
Eltrombopag stimulates the thrombopoietin receptor, encouraging the production of platelets in the bone marrow, which helps to prevent bleeding in people with low platelet counts.
Uses:
- Chronic immune thrombocytopenia (ITP): Used when other treatments fail.
- Thrombocytopenia from Hepatitis C: Helps manage low platelet counts during antiviral therapy.
- Severe Aplastic Anemia: For patients who do not respond to other treatments.
Side Effects: Common side effects include:
- Nausea, fatigue, and headache.
- Liver enzyme abnormalities.
- Risk of blood clots in some patients.
FDA Approval:
Eltrombopag was first approved by the FDA in November 2008 for the treatment of chronic ITP.
